Utilization of DBS within drug discovery: A simple 2D-LC-MS/MS system to minimize blood- and paper-based matrix effects from FTA elute™ DBS

Bioanalysis

Volumn 3, Issue 11, 2011, Pages 1253-1270

  Clark, Graeme T ^a   Haynes, Julian J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANDOXATRIL; DOFETILIDE; DRUG; FLUCONAZOLE; GABAPENTIN; METHANOL; MIDAZOLAM; PF 05218881; RANITIDINE; REVATROPATE; SOLVENT; UK 141495; UK 258300; UK 338003; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRIED BLOOD SPOT; DRUG ANALYSIS; DRUG DETERMINATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; PROCESS OPTIMIZATION;

ANIMALS; ARTIFACTS; BLOOD; BLOOD SPECIMEN COLLECTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DISCOVERY; GUANIDINES; INJECTIONS; ISOTHIOCYANATES; METHANOL; PAPER; RATS; SOLVENTS; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 79958739623     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.81     Document Type: Article

References (29)

1. Beaudette P, Bateman KP. Discovery stage pharmacokinetics using dried blood spots. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 809(1), 153-158 (2004). (Pubitemid 38998433)
2. Barfield M, Spooner N, Lad R, Parry S, Fowles S. Application of dried blood spots combined with HPLC-MS/MS for the quantification of acetaminophen in toxicokinetic studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 870(1), 32-37 (2008).
3. European Bioanalysis Forum. Connecting Strategies on Dried Blood Spots. Brussels, Beligium, 17-18 June 2010.
4. DIA/PhRMA. Workshop on Dried Blood Spot Sampling in the Pharmaceutical Industry: Methodology, Implementation and best Practices. Washington, DC, USA (2009).
5. Special Focus: Dried Blood Spots. Bioanalysis 2(11), 1781-1909 (2010).
6. Special Focus Issue: Dried Blood Spots. Bioanalysis 2(8), 1343-1522 (2010).
7. Buxton OM, Malarick K, Wang W, Seeman T. Changes in dried blood spot Hb A1c with varied postcollection conditions. Clin. Chem. 55(5), 1034-1036 (2009).
8. Hollegaard MV, Grove J, Thorsen P, Norgaard-Pedersen B, Hougaard DM. High-throughput genotyping on archived dried blood spot samples. Genet. Test Mol. Biomarkers 13(2), 173-179 (2009).
9. Wijnen PA, Op Den Buijsch RA, Cheung SC et al. Genotyping with a dried blood spot method: a useful technique for application in pharmacogenetics. Clin. Chim. Acta 388(1-2), 189-191 (2008). (Pubitemid 350266566)
10. Lad R. Validation of individual quantitative methods for determination of cytochrome P450 probe substrates in human dried blood spots with HPLC-MS/MS. Bioanalysis 2(11), 1849-1861 (2010).
11. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand-binding assays. Pharm. Res. 24(10), 1962-1973 (2007). (Pubitemid 47389236)
12. US FDA. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Rockville, MD, USA (2001).
13. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24(1), 49-65 (2010).
14. Clark GT, Haynes JJ, Bayliss Maj, Burrows L. Utilization of DBS within drug discovery: development of a serial microsampling pharmacokinetic study in mice. Bioanalysis 2(8), 1477-1488 (2010).
15. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(23), 2198-2207 (2009).
16. Larger PJ, Breda M, Fraier D, Hughes H, James CA. Ion-suppression effects in liquid chromatography-tandem mass spectrometry due to a formulation agent, a case study in drug-discovery bioanalysis. J. Pharm. Biomed. Anal. 39(1-2), 206-216 (2005). (Pubitemid 41112139)
17. Liu G, Patrone L, Snapp Hm et al. Evaluating and defining sample preparation procedures for DBS LC-MS/MS assays. Bioanalysis 2(8), 1405-1414 (2010).
18. Olah E, Fekete S, Fekete J, Ganzler K. Comparative study of new shell-type, sub-2-micron fully porous and monolith stationary phases, focusing on mass-transfer resistance. J. Chromatogr. A 1217(23), 3642-3653 (2010).
19. Gritti F, Leonardis I, Shock D, Stevenson P, Shalliker A, Guiochon G. Performance of columns packed with the new shell particles, Kinetex-C18. J. Chromatogr. A 1217(10), 1589-1603 (2010).
20. Gritti F, Guiochon G. Performance of columns packed with the new shell Kinetex-C18 particles in gradient elution chromatography. J. Chromatogr. A 1217(10), 1604-1615 (2010).
21. Kirkland JJ. Ultrafast reversed-phase high-performance liquid chromatographic separations: an overview. J. Chromatogr. Sci. 38(12), 535-544 (2000). (Pubitemid 34982756)
22. Xu Y, Mehl JT, Bakhtiar R, Woolf EJ. Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography-tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma. Anal. Chem. 82(16), 6877-6886 (2010).
23. Simpson M, Lappin G, Keely BJ. Development of 2D chiral chromatography with accelerator mass spectrometry for quantification of (14)C-labeled R-and S-verapamil in plasma. Bioanalysis 2(3), 397-405 (2010).
24. Sallustio BC. LC-MS/MS for immunosuppressant therapeutic drug monitoring. Bioanalysis 2(6), 1141-1153 (2010).
25. Bankefors J, Nord Li, Kenne L. Multidimensional profiling of components in complex mixtures of natural products for metabolic analysis, proof of concept: application to Quillaja saponins. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878(3-4), 471-476 (2009).
26. Heinig K, Bucheli F, Hartenbach R, Gajate-Perez A. Determination of mycophenolic acid and its phenyl glucuronide in human plasma, ultrafiltrate, blood, DBS and dried plasma spots. Bioanalysis 2(8), 1423-1435 (2010).
27. Heinig K, Bucheli F. Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 876(1), 129-136 (2008).
28. Haynes JJ, Jones H, Gibson D, Clark GT. Bioanalytical determination of unstable endogenous small peptides: RFRP3 and its metabolites in rat blood. Bioanalysis 3(7), 763-778 (2011).
29. Apffel A, Fischer S, Goldberg G, Goodley PC, Kuhlmann FE. Enhanced sensitivity for peptide mapping with electrospray liquid chromatography-mass spectrometry in the presence of signal suppression due to trifluoroacetic acid-containing mobile phases. J. Chromatogr. A 712(1), 177-190 (1995).